Jennifer Munson named director of Fralin Biomedical Research Institute at VTC's Cancer Research Center

Epigenetic research reveals a potential treatment for CRC and other solid tumors

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.

January 17, 2025

Vol.51 No.02

Clinical Roundup

CAR T cells armed with IL-15 show promise in treating solid cancers

A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.

December 06, 2024

Vol.50 No.45

Clinical Roundup

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

One-third of HER2-positive tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d’Hebron Institute of Oncology’s Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute, Barcelona, have developed novel chimeric antigen receptor T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells

Scientific progress often follows a prolonged path, but bioentrepreneur Samy Lamouille believes his dedication toward this pursuit will ultimately pay off for brain cancer patients.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Clinical Roundup

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.

October 04, 2024

Vol.50 No.37

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

YOU MAY BE INTERESTED IN

Epigenetic research reveals a potential treatment for CRC and other solid tumors

CAR T cells armed with IL-15 show promise in treating solid cancers

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

First-in-human study of novel inhibitor shows promise in MTAP-deleted solid tumors

Renew today!

Subscriber content

Never miss an issue!

Login